Regeneron Prescription drugs, Inc. (NASDAQ:REGN) forty third Annual J.P. Morgan Healthcare Convention 2025 January 13, 2025 5:15 PM ET
Firm Contributors
Leonard Schleifer – Board Co-Chair, Co-Founder, President and CEOGeorge Yancopoulos – Co-Founder, Board Co-Chair, President & CSO
Convention Name Contributors
Chris Schott – JPMorgan
Good afternoon, everyone. I am Chris Schott from J.P. Morgan, and it is my pleasure to be introducing Regeneron as we speak. From the corporate, we now have Regeneron’s co-Founders and co-Chairs, President and CEO, Len Schleifer, in addition to President and CSO, George Yancopoulos. With loads of updates on the core enterprise and truly notably the pipeline, very a lot wanting ahead to the presentation as we speak.
So we will have, Len and George make a presentation, after which we’ll have just a little fireplace chat after that. So with that, over to Len.
Leonard Schleifer
Thanks. Thanks, Chris, for that very detailed and heat introduction. Let’s have a look at if I can get the slides going right here. So that is our forward-looking assertion slide, and whilst you’re taking a look at that, I believed it would make sense for me to make just a few backward wanting statements.
I, as maybe the longest serving CEO within the biotechnology business and together with George, a part of the longest serving, administration group within the biotechnology business, I have been talking on this convention for greater than three many years. And whereas many issues have modified, there have been completely different themes. Is it a platform? Is it small molecules? Is it RNA? Is it vaccines? Is it biologics? Or that rotates and alter. There’s one fixed and the fixed is buyers at all times wish to know what’s that one factor that your organization has that ought to make us wish to make investments.
And within the early days of Regeneron, I answered that query in type of obtuse means. I mentioned, effectively it is
